The funds will be used to incorporate new advances into the FiCAT gene writing platform, validate various next generation CAR-T therapies in the preclinical phase and expand the FiCAT cell engineering...
The financing was led by SV Health Investors’ Dementia Discovery Fund, joined by a syndicate of leading international life science venture investors: British Business Bank, M Ventures, Novartis Vent...
Asabys joins SafeHeal’s global investor syndicate, which includes Sofinnova, Solar Eclipse and a Leading Multinational Life Sciences Corporation, bringing additional resources and strategic expertis...
Gyala Therapeutics is a biotechnology company focused on developing next-generation immunotherapies to treat hematological cancers with unmet medical needs. Its lead program is GYA01, a first-in-class...
Buenavista Equity Partners, through its specialized fund BV Healthcare Growth Innvierte I (BHG I) created in collaboration with Columbus Venture Partners, has announced its entry into the shareholding...
Under the terms of the strategic collaboration agreement, CSL will fully fund VarmX’s global Phase 3 EquilibriX-S trial evaluating VMX-C001 in patients taking FXa DOACs who require urgent surgery. C...
Columbus Life Sciences Fund V will primarily invest in European and U.S.-based technology companies in the fields of biotechnology, advanced therapies, medical devices, precision medicine, diagnostics...
The Series B extension financing was led by Bpifrance and joined by all existing shareholders, including AdBio Partners, CDTI Innovación, Columbus Venture Partners, European Innovation Council (EIC),...
The company focuses on researching and developing new technologies for the treatment of oncological diseases, with a particular focus on Glioblastoma, an aggressive brain tumor in urgent need of new t...
Founded in 2021 as a spin-off of Pompeu Fabra University, KOA Biotech was born with the mission of revolutionizing aquaculture through cutting-edge technology. The company is transforming health manag...
Invivo Ventures AI will target early-stage companies applying AI to advance biotechnology and other science-driven domains. The fund is designed to capitalize on the surging momentum in AI, with deal ...
Innvierte SICC of CDTI Innovación invests in Integra Therapeutics, together with three co-investors, to develop a gene-editing platform for the treatment of oncological, autoimmune, and genetic disea...